Folic acid decorated pH sensitive polydopamine coated honeycomb structured nickel oxide nanoparticles for targeted delivery of quercetin to triple negative breast cancer cells

Abstract

Targeted drug delivery is an advanced method that increases the concentration of drug in the specific targeted area in the body. It improves efficacy of treatment and reduces the side effects in drug administration. The use of nanoparticles enhances the bioavailability, in vivo stability, intestinal absorption, solubility, sustained and targeted delivery. Quercetin (Q) is an anticancer agent used in cancer models due to its antioxidant and antitumor properties. Folic acid (FA) is the ligand used to activate receptor mediated endocytosis for targeted delivery of Quercetin. Polydopamine (PD) is pH sensitive and also inhibits angiogenesis. The quinones of PD serves as anchoring points for FA conjugation. In this work, honeycomb structured Nickel oxide (NiO) nanoparticles loaded with quercetin, surface modified with FA and PD was synthesized to target triple negative breast cancer cells. NiO was characterized by XRD, FTIR, Raman Spectroscopy, BET analysis and Zeta Potential. The honeycomb structure was confirmed by SEM. NiO size and morphology was analyzed by TEM. The porous structure of NiO enabled the efficient loading of Quercetin. Hemolysis analysis showed NiO has good hemocompatibility. The drug release profile confirmed a pH sensitive and controlled delivery of Quercetin. The drug release profile expressed higher release at lower pH. The drug release kinetic profile unveils the primary release mechanism to be diffusion controlled. MTT assay were performed against Vero cell line and MDA-MB-231 breast cancer cell line. The nanoformulation showed reduced cytotoxicity and good biocompatibility on Vero cells and appreciable anti-cancer activity on MDA-MB-231 breast cancer cell line. • Honeycomb structured NiO nanoparticle for drug encapsulation. • pH sensitive nanocarrier for controlled release. • Folate receptor alpha (FOLR1) mediated endocytosis of nanoconjugate. • Anticancer activity against MDA-MB-231 breast cancer cell line.